This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC).
The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to the combination treatment. Stopping treatment due to side effects was rare.
The response of patients to the treatments (i.e. the cancer getting smaller) and the time to when the treatment stopped working and the cancer started growing again (progression-free survival) were comparable in the two dose groups, with over 50% of patients responding to therapy.
Combination therapy with atezolizumab and cabozantinib caused a response in the majority of patients with both clear cell and non–clear cell RCC, and was tolerable for most patients.